A Platform Study of In Vivo CAR-T for Treating Advanced Malignant Tumors Based on Target Screening
Recruiting now · Early Phase 1
Conditions studied: Advanced Malignant Tumours
In brief
This is a single-arm, open-label, single-center, dose-escalation Phase I platform study designed to evaluate the safety, tolerability, preliminary efficacy, pharmacokinetics, and pharmacodynamics of an in vivo CAR-T therapy (V001 Injection, targeting BCMA, GPRC5D, DLL3,FcRH5, etc.) in patients with advanced malignant tumors.
Key facts
- Study ID
- NCT07395479
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- People needed
- 50
- Starts
- 2025-11-21
- Expected to finish
- 2027-12-01
- Last updated by the study team
- 2026-05-13
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age ≥ 18 years.
- Histologically confirmed advanced hematological malignancies (e.g., multiple myeloma, lymphoma) or solid tumors (e.g., small cell lung cancer) that are relapsed or refractory.
- Tumor cells express the relevant target (e.g., BCMA, GPRC5D, DLL3) as required for the specific cohort.
- ECOG performance status 0-2 (hematological malignancies) or 0-1 (solid tumors) and life expectancy ≥ 3 months.
- Adequate organ function (e.g., creatinine clearance ≥45 mL/min, LVEF ≥45%).
- Patients of childbearing potential must agree to use effective contraception during the study and for 1 year after dosing.
- Signed informed consent form.
You may not qualify if…
- Active, uncontrolled infection.
- Active central nervous system metastases or involvement.
- Prior anticancer therapy, radiotherapy, or investigational therapy within specified timeframes before the first study dose.
- Severe cardiac or pulmonary disease (e.g., NYHA Class III/IV heart failure), severe hepatic or renal impairment.
- Active Hepatitis B, Hepatitis C, HIV, or syphilis infection.
- Prior allogeneic hematopoietic stem cell transplantation (within specified window) or active graft-versus-host disease.
- Pregnancy or lactation.
- History of severe allergy to any components of the investigational product.
- Any other condition deemed by the investigator to increase risk or interfere with study results.
Where it is running
- Cancer Hospital Chinese Academy of Medical Sciences 17 Panjiayuan Nanli, Chaoyang District — Beijing, Beijing Municipality, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.